Source-grounded facts extracted from Health Catalyst, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Health Catalyst, Inc. entered into Unit Purchase Agreement with Med-Metrix, LLC valued at $147 million (effective 2026-06-04).
“On June 4, 2026, Health Catalyst, Inc. ("Health Catalyst") entered into a Unit Purchase Agreement (the "Purchase Agreement") with Med-Metrix, LLC ("Buyer")”
Health Catalyst, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 11, 2026 , Health Catalyst, Inc. (the "Company") issued a press release relating to its financial results for the quarter ended March 31, 2026 .”
Steven Nelson was appointed as Board Member at Health Catalyst, Inc..
“the board of directors (our Board) of Health Catalyst, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Steven Nelson to the Board, effective May 1, 2026.”
Health Catalyst, Inc. reported the year ended December 31, 2025 results: revenue $311.1 million, net income $ (177,974).
“We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,”
Health Catalyst, Inc. reported the quarter ended December 31, 2025 results: revenue $ 74,679, net income $ (91,025).
“Months Ended December 31, Year over Year Change 2025 2024 2025 2024 GAAP Financial Measures: (in thousands, except percentages) (in thousands, except percentages) Total revenue $ 74,679 $ 79,606 (6)% $ 311,136 $ 306,584 1% Gross profit $ 31,385 $ 28,618 10% $ 120,356 $ 114,503 5% Gross margin 42.0 % 35.9 % 38.7 % 37.3 % Net loss $ (91,025) $ (20,673) (340)% $”
Anita Pramoda resigned as Director at Health Catalyst, Inc..
“On February 20, 2025, Anita Pramoda informed the Board of her resignation from the Board, and on February 20, 2025, the Board accepted her resignation, including her resignation from the compensation committee and transactions committee of the Board, effective March 1, 2025.”
Jill Hoggard Green was appointed as Director at Health Catalyst, Inc..
“On November 2, 2024, the board of directors (the “Board”) of the Company, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Jill Hoggard Green to the Board, effective December 1, 2024.”
Health Catalyst, Inc. reported the quarter ended March 31, 2024 results: revenue $74.7 million.
“today reported financial results for the quarter ended March 31, 2024. “For the first quarter of 2024, I am pleased by our strong financial results, including total revenue of $74.7 million and Adjusted EBITDA of $3.4 million, with these results beating the mid-point of our quarterly guidance on each metric. This financial performance demonstrates our ability to”
Daniel LeSueur was appointed as Chief Operating Officer at Health Catalyst, Inc..
“On February 22, 2024, the Company announced that Daniel LeSueur, age 45, the Company’s Senior Vice President and General Manager of the Professional Services Business Unit, will assume the role of Chief Operating Officer and principal operating officer of the Company, effective March 1, 2024.”
Jason Alger was appointed as Chief Financial Officer at Health Catalyst, Inc..
“On February 22, 2024, the Company announced that Jason Alger, age 40, the Company’s Chief Accounting Officer and principal accounting officer, will assume the role of Chief Financial Officer and principal financial officer of the Company, effective March 1, 2024.”
Bryan Hunt resigned as Chief Financial Officer at Health Catalyst, Inc..
“On February 16, 2024, Bryan Hunt informed the board of directors of the Company (the Board) of, and on February 20, 2024, the Board accepted, his resignation as the Company's Chief Financial Officer and principal financial officer, effective March 1, 2024.”
Health Catalyst, Inc. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).
“On February 22, 2024, Health Catalyst, Inc. (the Company) issued a press release relating to its financial results for the quarter and year ended December 31, 2023. A copy of the press release, the summary of the Company's 2023 Financial Highlights, 2024 Guidance & Key Themes, and the summary of the Company’s Updated Growth and Financial Targets are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and each are incorporated herein by reference.”
Health Catalyst, Inc. reported the quarter ended September 30, 2023 results: revenue $73.8 million, net income $(22,032) thousand. Guidance raised.
“reported financial results for the quarter ended September 30, 2023. “For the third quarter of 2023, I am pleased by our strong financial results, including total revenue of $73.8 million and Adjusted EBITDA of $2.0 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise”
Health Catalyst, Inc. reported the quarter ended September 30, 2023 results: revenue $73.8 million. Guidance raised.
“timing. See below for quarterly conference call details. “For the third quarter of 2023, I am pleased by our strong preliminary financial results, including total revenue of $73.8 million and Adjusted EBITDA of $2.0 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise”
Health Catalyst, Inc. reported the quarter ended June 30, 2023 results: revenue $73.2 million. Guidance raised.
“today reported financial results for the quarter ended June 30, 2023. “For the second quarter of 2023, we are encouraged by our financial results, including total revenue of $73.2 million and Adjusted EBITDA of $3.5 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, given that we are tracking slightly ahead of”
Health Catalyst, Inc. shareholders approved Advisory, non-binding vote to approve the compensation of the Company’s named executive officers at the 2023-06-14 meeting.
“Proposal 3 – Advisory, Non-Binding Vote to Approve the Compensation of the Company’s Named Executive Officers The stockholders approved the advisory, non-binding proposal to approve the compensation of the Company’s named executive officers. The results of such vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 40,672,307 1,663,691 14,419 5,056,358”
Health Catalyst, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“Proposal 2 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP to perform the audit of the Company’s consolidated financial statements for the fiscal year ending December 31, 2023. The results of such vote were as follows: Votes For Votes Against Abstentions 47,292,765 108,336 5,674”
Health Catalyst, Inc. shareholders approved Election of two Class I directors to serve three-year terms expiring at the 2026 annual meeting at the 2023-06-14 meeting.
“Proposal 1 – Election of Directors The Company’s stockholders elected each of the two persons named below to serve as a Class I director of the Company to serve a three-year term expiring at the 2026 annual meeting of the stockholders or until their successors are duly elected and qualified, subject to their earlier removal or resignation. The results of such vote were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Anita V. Pramoda 30,037,200 12,313,217 5,056,358 S. Dawn Smith 30,403,681 11,946,736 5,056,358”
Health Catalyst, Inc. reported the quarter ended March 31, 2023 results: revenue $73,868, net income $(33,190).
“GAAP Financial Data: (in thousands, except percentages, unaudited) Technology revenue $ 47,186 $ 42,230 12% Professional services revenue $ 26,682 $ 25,857 3% Total revenue $ 73,868 $ 68,087 8% Loss from operations $ (34,914) $ (24,347) (43)% Net loss $ (33,190) $ (22,458) (48)% Other Non-GAAP Financial Data: (1) Adjusted Technology Gross Profit $ 32,958 $”
Benjamin Landry was appointed as General Counsel and Corporate Secretary at Health Catalyst, Inc..
“On March 30, 2023, the Company announced that Benjamin Landry, age 41, the Company’s Assistant General Counsel, will assume the role of General Counsel and Corporate Secretary of the Company, effective May 1, 2023.”
Daniel Orenstein resigned as General Counsel and Corporate Secretary at Health Catalyst, Inc..
“On March 24, 2022, Daniel Orenstein provided notice to the Company that, effective April 30, 2023, Mr. Orenstein will step down from his position as General Counsel and Corporate Secretary of the Company to pursue other opportunities.”
Anne Marie Bickmore was appointed as Chief Operating Officer and Chief Product Officer at Health Catalyst, Inc..
“On March 30, 2023, Health Catalyst, Inc. (the “ Company ”) announced that Anne Marie Bickmore, age 60, the Company’s Chief Product Officer, will assume the role of Chief Operating Officer and Chief Product Officer of the Company, effective April 3, 2023.”
Health Catalyst, Inc. reported Twelve Months Ended December 31, 2022 results: revenue $ 276,236, net income $ (137,403).
“Financial Highlights for the Three and Twelve Months Ended December 31, 2022 Key Financial Metrics Three Months Ended December 31, Year over Year Change Twelve Months Ended December 31, Year over Year Change 2022 2021 2022 2021 GAAP Financial Data: (in thousands, except percentages) (in thousands, except percentages) Technology revenue $ 44,664 $ 40,088 11% $ 176,288 $ 147,718 19% Professional services revenue $ 24,498 $ 24,628 (1)% $ 99,948 $ 94,208 6% Total revenue $ 69,162 $ 64,716 7% $ 276,236 $ 241,926 14% Loss from operations $ (36,745) $ (44,765) 18% $ (140,005) $ (143,650) 3% Net loss $ (35,782) $ (48,992) 27% $ (137,403) $ (153,210) 10%”
Health Catalyst, Inc. reported Three Months Ended December 31, 2022 results: revenue $ 69,162, net income $ (35,782).
“Financial Highlights for the Three and Twelve Months Ended December 31, 2022 Key Financial Metrics Three Months Ended December 31, Year over Year Change Twelve Months Ended December 31, Year over Year Change 2022 2021 2022 2021 GAAP Financial Data: (in thousands, except percentages) (in thousands, except percentages) Technology revenue $ 44,664 $ 40,088 11% $ 176,288 $ 147,718 19% Professional services revenue $ 24,498 $ 24,628 (1)% $ 99,948 $ 94,208 6% Total revenue $ 69,162 $ 64,716 7% $ 276,236 $ 241,926 14% Loss from operations $ (36,745) $ (44,765) 18% $ (140,005) $ (143,650) 3% Net loss $ (35,782) $ (48,992) 27% $ (137,403) $ (153,210) 10%”
Matthew Kolb was appointed as Director at Health Catalyst, Inc..
“On February 27, 2023, the board of directors (the “Board”) of Health Catalyst, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Kolb to the Board, effective July 1, 2023.”
Paul Horstmeier departed as Chief Operating Officer at Health Catalyst, Inc..
“On December 30, 2022, Paul Horstmeier provided notice to Health Catalyst, Inc. (the “Company”) that he will step down from his position as Chief Operating Officer of the Company, effective March 31, 2023 (the “Separation Date”), due to Mr. Horstmeier being called by the leadership of the Church of Jesus Christ of Latter-Day Saints to serve for 3 years as Mission President of the Puerto Rico San Juan Mission, beginning in June 2023 .”
J. Patrick Nelli departed as Senior Advisor at Health Catalyst, Inc..
“On December 30, 2022, Mr. Nelli and the Company entered into a separation agreement (the “Separation Agreement”) in connection with Mr. Nelli’s departure from the Company, effective December 31, 2022.”
Health Catalyst, Inc. reported the quarter ended September 30, 2022 results: revenue $68,354, net income $(45,735). Guidance raised.
“GAAP Financial Data: (in thousands, except percentages, unaudited) Technology revenue $ 43,997 $ 38,262 15% Professional services revenue $ 24,357 $ 23,475 4% Total revenue $ 68,354 $ 61,737 11% Loss from operations $ (45,721) $ (42,249) (8)% Net loss $ (45,735) $ (40,014) (14)% Other Non-GAAP Financial Data: (1) Adjusted Technology Gross Profit $ 29,993 $”
J. Patrick Nelli changed role as Senior Advisor at Health Catalyst, Inc..
“J. Patrick Nelli and Health Catalyst, Inc. (the “Company”) mutually agreed that, effective September 30, 2022, Mr. Nelli will transition from his position as President of the Company to Senior Advisor”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.